Institution
University of Erlangen-Nuremberg
Education•Erlangen, Bayern, Germany•
About: University of Erlangen-Nuremberg is a education organization based out in Erlangen, Bayern, Germany. It is known for research contribution in the topics: Population & Immune system. The organization has 42405 authors who have published 85600 publications receiving 2663922 citations.
Topics: Population, Immune system, Breast cancer, Catalysis, Transplantation
Papers published on a yearly basis
Papers
More filters
••
University of Cincinnati1, Harvard University2, University of Tübingen3, Davis Phinney Foundation4, University of Erlangen-Nuremberg5, Toronto Western Hospital6, Great Lakes Institute of Management7, University of Rochester8, Michael J. Fox Foundation9, Instituto Superior de Ciências da Saúde Egas Moniz10, Tel Aviv University11, Radboud University Nijmegen12
TL;DR: The work carried out by the task force toward identifying challenges and opportunities in the development of technologies with potential for improving the clinical management and the quality of life of individuals with PD is summarized.
Abstract: The miniaturization, sophistication, proliferation, and accessibility of technologies are enabling the capture of more and previously inaccessible phenomena in Parkinson's disease (PD). However, more information has not translated into a greater understanding of disease complexity to satisfy diagnostic and therapeutic needs. Challenges include noncompatible technology platforms, the need for wide-scale and long-term deployment of sensor technology (among vulnerable elderly patients in particular), and the gap between the "big data" acquired with sensitive measurement technologies and their limited clinical application. Major opportunities could be realized if new technologies are developed as part of open-source and/or open-hardware platforms that enable multichannel data capture sensitive to the broad range of motor and nonmotor problems that characterize PD and are adaptable into self-adjusting, individualized treatment delivery systems. The International Parkinson and Movement Disorders Society Task Force on Technology is entrusted to convene engineers, clinicians, researchers, and patients to promote the development of integrated measurement and closed-loop therapeutic systems with high patient adherence that also serve to (1) encourage the adoption of clinico-pathophysiologic phenotyping and early detection of critical disease milestones, (2) enhance the tailoring of symptomatic therapy, (3) improve subgroup targeting of patients for future testing of disease-modifying treatments, and (4) identify objective biomarkers to improve the longitudinal tracking of impairments in clinical care and research. This article summarizes the work carried out by the task force toward identifying challenges and opportunities in the development of technologies with potential for improving the clinical management and the quality of life of individuals with PD. © 2016 International Parkinson and Movement Disorder Society.
428 citations
••
TL;DR: Adjusting pharmacokinetics to the individual patient should improve the precision of target-controlled infusion and may help to broaden the field of application for target- controlled infusion systems.
Abstract: Background:Target-controlled infusion is an increasingly common type of administration for propofol. This method requires accurate knowledge of pharmacokinetics, including the effects of age and weight. The authors performed a multicenter population analysis to quantitate the effects of covariates.M
428 citations
••
TL;DR: The Symplicity HTN-2, a multicenter, randomized trial, demonstrated that catheter-based renal denervation produced significant blood pressure lowering in treatment-resistant patients at 6 months after the procedure compared with control, medication-only patients.
Abstract: Background—Renal sympathetic nerve activation contributes to the pathogenesis of hypertension. Symplicity HTN-2, a multicenter, randomized trial, demonstrated that catheter-based renal denervation produced significant blood pressure lowering in treatment-resistant patients at 6 months after the procedure compared with control, medication-only patients. Longer-term follow-up, including 6-month crossover results, is now presented. Methods and Results—Eligible patients were on ≥3 antihypertensive drugs and had a baseline systolic blood pressure ≥160 mm Hg (≥150 mm Hg for type 2 diabetics). After the 6-month primary end point was met, renal denervation in control patients was permitted. One-year results on patients randomized to immediate renal denervation (n=47) and 6-month postprocedure results for crossover patients are presented. At 12 months after the procedure, the mean fall in office systolic blood pressure in the initial renal denervation group (−28.1 mm Hg; 95% confidence interval, −35.4 to −20.7; P<...
425 citations
••
TL;DR: In this article, a silicon optomechanical circuit with both optical and mechanical connectivity between two optical cavities was designed and fabricated to enable non-reciprocal transport of photons with 35 dB isolation.
Abstract: Synthetic magnetism has been used to control charge neutral excitations for applications ranging from classical beam steering to quantum simulation. In optomechanics, radiation-pressure-induced parametric coupling between optical (photon) and mechanical (phonon) excitations may be used to break time-reversal symmetry, providing the prerequisite for synthetic magnetism. Here we design and fabricate a silicon optomechanical circuit with both optical and mechanical connectivity between two optomechanical cavities. Driving the two cavities with phase-correlated laser light results in a synthetic magnetic flux, which, in combination with dissipative coupling to the mechanical bath, leads to non-reciprocal transport of photons with 35 dB of isolation. Additionally, optical pumping with blue-detuned light manifests as a particle non-conserving interaction between photons and phonons, resulting in directional optical amplification of 12 dB in the isolator through-direction. These results suggest the possibility of using optomechanical circuits to create a more general class of non-reciprocal optical devices, and further, to enable new topological phases for both light and sound on a microchip.
425 citations
••
TL;DR: A poor initial hematopoietic response to darbepoetin alfa was associated with an increased subsequent risk of death or cardiovascular events as doses were escalated to meet target hemoglobin levels.
Abstract: Patients who had a poor initial response to darbepoetin alfa had a lower average hemoglobin level at 12 weeks and during follow-up than did patients with a better hemoglobin response (a change in hemoglobin level ranging from 2 to 15% or more) (P<0.001 for both comparisons), despite receiving higher doses of darbepoetin alfa (median dose, 232 μg vs. 167 μg; P<0.001). Patients with a poor response, as compared with those with a better response, had higher rates of the composite cardiovascular end point (adjusted hazard ratio, 1.31; 95% confidence interval [CI], 1.09 to 1.59) or death (adjusted hazard ratio, 1.41; 95% CI, 1.12 to 1.78). Conclusions A poor initial hematopoietic response to darbepoetin alfa was associated with an increased subsequent risk of death or cardiovascular events as doses were escalated to meet target hemoglobin levels. Although the mechanism of this differential effect is not known, these findings raise concern about current target-based strategies for treating anemia in patients with chronic kidney disease. (Funded by Amgen; ClinicalTrials.gov number, NCT00093015.)
424 citations
Authors
Showing all 42831 results
Name | H-index | Papers | Citations |
---|---|---|---|
Hermann Brenner | 151 | 1765 | 145655 |
Richard B. Devereux | 144 | 962 | 116403 |
Manfred Paulini | 141 | 1791 | 110930 |
Daniel S. Berman | 141 | 1363 | 86136 |
Peter Lang | 140 | 1136 | 98592 |
Joseph Sodroski | 138 | 542 | 77070 |
Richard J. Johnson | 137 | 880 | 72201 |
Jun Lu | 135 | 1526 | 99767 |
Michael Schmitt | 134 | 2007 | 114667 |
Jost B. Jonas | 132 | 1158 | 166510 |
Andreas Mussgiller | 127 | 1059 | 73778 |
Matthew J. Budoff | 125 | 1449 | 68115 |
Stefan Funk | 125 | 506 | 56955 |
Markus F. Neurath | 124 | 934 | 62376 |
Jean-Marie Lehn | 123 | 1054 | 84616 |